📊 BHVN Key Takeaways
Investment Thesis
Biohaven is a pre-revenue pharmaceutical company with severe financial deterioration, burning $610.2M in free cash flow annually while generating zero revenue. Despite maintaining adequate cash reserves of $230M, the company's negative profitability ratios, massive operating losses of $745.4M, and lack of commercial traction indicate fundamental operational distress that cannot be sustained without significant capital raises or revenue generation.
BHVN Strengths
- Strong cash position of $230M provides runway for operations
- Healthy current ratio of 3.18x demonstrates adequate short-term liquidity
- Minimal debt burden with 0.00x debt-to-equity ratio reduces financial leverage risk
BHVN Risks
- Complete absence of revenue generation with no clear commercialization timeline
- Operating cash burn of $609.4M annually will deplete cash reserves in approximately 15 months at current burn rate
- Massive net losses of $738.8M and negative ROE of -1418.8% indicate inability to create shareholder value
- No positive operating metrics or profitability indicators across any measurement
- Dependent on successful drug development and FDA approval with no guaranteed outcomes
Key Metrics to Watch
- Path to revenue generation and commercial product launches
- Monthly cash burn rate and remaining cash runway
- Clinical trial progress and FDA approval timelines
- Capital raise activities and dilution impact on shareholders
BHVN Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.18x current ratio provides a solid financial cushion.
BHVN Profitability Ratios
BHVN vs Healthcare Sector
How Biohaven Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BHVN Balance Sheet & Liquidity
BHVN 5-Year Financial Trend
5-Year Trend Summary: Biohaven Ltd.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-5.73 indicates the company is currently unprofitable.
BHVN Growth Metrics (YoY)
BHVN Capital Allocation
BHVN SEC Filings
Access official SEC EDGAR filings for Biohaven Ltd. (CIK: 0001935979)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BHVN
What is the AI rating for BHVN?
Biohaven Ltd. (BHVN) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BHVN's key strengths?
Strong cash position of $230M provides runway for operations. Healthy current ratio of 3.18x demonstrates adequate short-term liquidity.
What are the risks of investing in BHVN?
Complete absence of revenue generation with no clear commercialization timeline. Operating cash burn of $609.4M annually will deplete cash reserves in approximately 15 months at current burn rate.
What is BHVN's revenue and growth?
Biohaven Ltd. reported revenue of N/A.
Does BHVN pay dividends?
Biohaven Ltd. does not currently pay dividends.
Where can I find BHVN SEC filings?
Official SEC filings for Biohaven Ltd. (CIK: 0001935979) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BHVN's EPS?
Biohaven Ltd. has a diluted EPS of $-6.86.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.